ClinicalTrials.gg
CompletedNCT00415519Updated Jul 21, 2026Results posted

Efficacy and Safety Study of MCI-186 for Treatment of Amyotrophic Lateral Sclerosis (ALS) Who Met Severity Classification III

A Phase 3 interventional study of MCI-186 and Placebo of MCI-186 in Amyotrophic Lateral Sclerosis (ALS), sponsored by Shionogi. Completed. Open to participants aged 20 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-07-21.

Sponsored by Shionogi · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
25
Allocation
Randomized
Ages
20 Years to 75 Years
Sex
All
01

Study summary

The primary objective of this study is to evaluate the efficacy of 60mg of MCI-186 via intravenous drip once a day in patients with ALS whose severity is classified as grade III, based on the changes in the revised ALS functional rating scale (ALSFRS-R) scores after 24 weeks administration in double-blind, placebo-controlled manner. And in addition, this study will be performed to examine the safety of MCI-186 to ALS patients who met severity classification III.

02

Conditions studied

  • Amyotrophic Lateral Sclerosis (ALS)

Keywords

  • Amyotrophic lateral sclerosis
  • free radical scavenger
03

In context

Amyotrophic Lateral Sclerosis

980 studies on the registry are indexed under Amyotrophic Lateral Sclerosis; 279 are open to participants now.

This study's enrollment of 25 is below the median of 38 across 664 interventional studies indexed under Amyotrophic Lateral Sclerosis.

Browse Amyotrophic Lateral Sclerosis studies →

Lead sponsor

Shionogi is the lead sponsor of 105 studies on the registry; 10 are open to participants now.

Of its 39 completed or terminated interventional studies of FDA-regulated products, 21 (54%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
20 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients who are defined as "definite ALS," "probable ALS" or "probable-laboratory-supported ALS," met diagnostic criteria revised EL Escorial for Airlie House.
  • Patients who cannot take at least one action of eating a meal, excreting, or moving with oneself alone, and need assistance in everyday life.
  • Patients whose progress of the condition during 12 weeks before administration meet other requirements.

Exclusion criteria

Exclusion Criteria:

  • Patients judged to be inadequate to participate in this study by their physician, because those patients' general condition deteriorated to the point that they need to be hospitalized for severe hepatic disease, sever heart disease, sever renal disease and so on, or they need to be administered antibiotics to infection.
  • Patients who complain the difficulty in breathing caused by deteriorating the respiratory function.
  • Patients with such complications as Parkinson's disease, schizophrenia, dementia, renal failure, or other severe complication, and patients who have the anamnesis of to edaravone.
  • Pregnant, lactating, and probably pregnant patients, and patients who want to become pregnant, and patients who can not agree to .
  • Patients who have been administered other products within 12 weeks before consent, or who are participating in other clinical trials at present.
  • In addition to the above exclusion criteria, patients judged to be inadequate to participate in this study by their physician.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
25 participants (actual)

Study arms

  • Experimental
    1

    Drug: MCI-186

  • Placebo comparator
    2

    Drug: Placebo of MCI-186

Interventions

  • Two ampoules (60 mg) of MCI-186 injection are intravenously administered once a day, for successive 14 days, followed by 14 days observation period (first cycle). Then treatment (10 days' administration during 14 days) - observation (14 days) cycle is repeated five times (2nd-6th cycles).

    Also known as: Edaravone, Radicut

  • DrugPlacebo of MCI-186

    Two ampoules of Placebo injection are intravenously administered once a day, for successive 14 days, followed by 14 days observation period (first cycle). Then treatment (10 days' administration during 14 days) - observation (14 days) cycle is repeated five times (2nd-6th cycles).

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Revised ALS Functional Rating Scale (ALSFRS-R) Score in Full Analysis Set (FAS) Population at 24 Weeks

    No primary endpoint was used, because various exploratory analyses were performed. 0=worst; 48=best

    Time frame: baseline and 24 weeks

  2. Death or a Specified State of Disease Progression

    No primary endpoint was used, because various exploratory analyses were performed. Any of "death, disability of independent ambulation, loss of upper arm function, tracheotomy, use of respirator, and use of tube feeding" was defined as an event.

    Time frame: 24 weeks

  3. Change From Baseline in % Forced Vital Capacity (%FVC) in Full Analysis Set (FAS) Population at 24 Weeks

    No primary endpoint was used, because various exploratory analyses were performed.

    Time frame: baseline and 24 weeks

  4. Percentage of Participants With Adverse Events

    No primary endpoint was used, because various exploratory analyses were performed.

    Time frame: 24 weeks

  5. Percentage of Participants With Adverse Drug Reactions

    No primary endpoint was used, because various exploratory analyses were performed.

    Time frame: 24 weeks

  6. The Percentage of Participants With an Abnormal Change in Laboratory Tests That Occurred in More Than Two Patients

    No primary endpoint was used, because various exploratory analyses were performed.

    Time frame: 24 weeks

  7. Percentage of Participants With Abnormal Changes in Sensory Examinations

    No primary endpoint was used, because various exploratory analyses were performed.

    Time frame: 24 weeks

07

Results

Posted Dec 20, 2017

Participant flow

Participant flow — Overall Study
MilestoneMCI-186Placebo of MCI-186
Started1312
Completed912
Not completed40
Withdrew: Adverse event10
Withdrew: Withdrawal by subject20
Withdrew: Patient's convenience10

Outcome measures

PrimaryChange From Baseline in Revised ALS Functional Rating Scale (ALSFRS-R) Score in Full Analysis Set (FAS) Population at 24 Weeks

No primary endpoint was used, because various exploratory analyses were performed. 0=worst; 48=best

Time frame:
baseline and 24 weeks
Reported as:
Least squares mean · units on a scale
Change From Baseline in Revised ALS Functional Rating Scale (ALSFRS-R) Score in Full Analysis Set (FAS) Population at 24 Weeks
units on a scaleMCI-186Placebo of MCI-186
Change From Baseline in Revised ALS Functional Rating Scale (ALSFRS-R) Score in Full Analysis Set (FAS) Population at 24 Weeks-6.52 ± 1.78-6 ± 1.83
PrimaryDeath or a Specified State of Disease Progression

No primary endpoint was used, because various exploratory analyses were performed. Any of "death, disability of independent ambulation, loss of upper arm function, tracheotomy, use of respirator, and use of tube feeding" was defined as an event.

Time frame:
24 weeks
Reported as:
Number · events
Death or a Specified State of Disease Progression
eventsMCI-186Placebo of MCI-186
death10
disability of independent ambulation42
loss of upper arm function12
tracheotomy00
use of respirator00
use of tube feeding10
PrimaryChange From Baseline in % Forced Vital Capacity (%FVC) in Full Analysis Set (FAS) Population at 24 Weeks

No primary endpoint was used, because various exploratory analyses were performed.

Time frame:
baseline and 24 weeks
Reported as:
Least squares mean · percentage of FVC
Change From Baseline in % Forced Vital Capacity (%FVC) in Full Analysis Set (FAS) Population at 24 Weeks
percentage of FVCMCI-186Placebo of MCI-186
Change From Baseline in % Forced Vital Capacity (%FVC) in Full Analysis Set (FAS) Population at 24 Weeks-18.75 ± 4.58-15.69 ± 4.58
PrimaryPercentage of Participants With Adverse Events

No primary endpoint was used, because various exploratory analyses were performed.

Time frame:
24 weeks
Reported as:
Number · percentage of participants
Percentage of Participants With Adverse Events
percentage of participantsMCI-186Placebo of MCI-186
Percentage of Participants With Adverse Events92.3100
PrimaryPercentage of Participants With Adverse Drug Reactions

No primary endpoint was used, because various exploratory analyses were performed.

Time frame:
24 weeks
Reported as:
Number · percentage of participants
Percentage of Participants With Adverse Drug Reactions
percentage of participantsMCI-186Placebo of MCI-186
Percentage of Participants With Adverse Drug Reactions23.18.3
PrimaryThe Percentage of Participants With an Abnormal Change in Laboratory Tests That Occurred in More Than Two Patients

No primary endpoint was used, because various exploratory analyses were performed.

Time frame:
24 weeks
Reported as:
Number · percentage of participants
The Percentage of Participants With an Abnormal Change in Laboratory Tests That Occurred in More Than Two Patients
percentage of participantsMCI-186Placebo of MCI-186
White blood cell count (WBC)23.18.3
Other laboratory tests except for WBC00
PrimaryPercentage of Participants With Abnormal Changes in Sensory Examinations

No primary endpoint was used, because various exploratory analyses were performed.

Time frame:
24 weeks
Reported as:
Number · percentage of participants
Percentage of Participants With Abnormal Changes in Sensory Examinations
percentage of participantsMCI-186Placebo of MCI-186
Numbness00
Staggering100
Vibratory sensation00

Adverse events

Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
MCI-186—3/13 (23.1%)12/13 (92.3%)
Placebo of MCI-186—2/12 (16.7%)12/12 (100%)
Most frequent serious events
Most frequent serious events
EventMCI-186Placebo of MCI-186
DysphagiaGastrointestinal disorders2/130/12
Musculoskeletal disorderMusculoskeletal and connective tissue disorders1/131/12
Pelvic venous thrombosisVascular disorders0/131/12
Gait disturbanceGeneral disorders1/130/12
DyspnoeaRespiratory, thoracic and mediastinal disorders1/130/12
Respiratory failureRespiratory, thoracic and mediastinal disorders1/130/12
Most frequent other events
Showing 10 of 53
Most frequent other events
EventMCI-186Placebo of MCI-186
DyscheziaGastrointestinal disorders0/133/12
StomatitisGastrointestinal disorders0/133/12
DiarrhoeaGastrointestinal disorders3/131/12
Gait disturbanceGeneral disorders3/131/12
HeadacheNervous system disorders3/132/12
Upper respiratory tract inflammationRespiratory, thoracic and mediastinal disorders3/131/12
NasopharyngitisInfections and infestations2/132/12
Joint sprainInjury, poisoning and procedural complications0/132/12
MyalgiaMusculoskeletal and connective tissue disorders0/132/12
ConstipationGastrointestinal disorders2/130/12

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)MCI-186Placebo of MCI-186Total
<=18 years000
Between 18 and 65 years111021
>=65 years224
Sex: Female, Male
Sex: Female, Male(Participants)MCI-186Placebo of MCI-186Total
Female6612
Male7613
08

Study locations

No study locations are listed for this record.

09

References and documents

Publications

  • WRITING GROUP ON BEHALF OF THE EDARAVONE (MCI-186) ALS 18 STUDY GROUP. Exploratory double-blind, parallel-group, placebo-controlled study of edaravone (MCI-186) in amyotrophic lateral sclerosis (Japan ALS severity classification: Grade 3, requiring assistance for eating, excretion or ambulation). Amyotroph Lateral Scler Frontotemporal Degener. 2017 Oct;18(sup1):40-48. doi: 10.1080/21678421.2017.1361441. PubMed 28872915 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2006 to primary completion in Jul 2008, 19 months.

Results were first posted in Dec 2017, 9 years 4 months after primary completion.

Of 24 phase 3 interventional studies under Amyotrophic Lateral Sclerosis, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 60. This study's 19 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 22, 2006
First posted
Dec 25, 2006
StartActual
Dec 31, 2006
Primary completionActual
Jul 31, 2008
CompletionActual
Jul 31, 2008
Results first posted
Dec 20, 2017
Last update
Jul 21, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 21, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00415519
Lead sponsor
Shionogi
Responsible party
Sponsor
First posted
Dec 25, 2006
Start date
Dec 31, 2006
Primary completion
Jul 31, 2008
Completion
Jul 31, 2008
Results posted
Dec 20, 2017
Last update
Jul 21, 2026

Study contacts

Shionogi Clinical Trials Administrator Clinical Support Help Line
study director · Shionogi

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Edaravone

Start the discussion